

Project: Fababean disease management
Trial: AM1102
District: Bellata
Variety: Doza
Sown: 20/04/2011

Disclaimer:

This document is based on the results from an individual trial and may contain experimental use patterns that are currently off-label. **This document does not provide any interpretation and should not be taken as an endorsement of any unregistered use pattern.**

Professional advice should be sought for specific recommendations to ensure access to the most up to date information and knowledge.

Any product referred to in this document must be used strictly as directed, and in accordance with all label or permit instructions. Always consult the label prior to use.

T1	Application date:	Crop stage:						
	13/06/2011	Grower applied						
	2/07/2011	1m height						
	14/09/2011	2m height						
Trt No.	Products T1	Products T2	Rate T2 ml or g/ha	Products T3	Rate T3 ml or g/ha	Severity (% of leaf area affected with disease/senescence)	Incidence (% of leaflets with disease/ senescence)	Yield t/ha
						5/10/2011 95 DAT2		4/11/2011
1		Nil	-	-	-	35	75	4.2
2		Mancozeb	1000	-	-	35	82	4.0
3		Mancozeb	1000	Mancozeb	1000	27	68	4.2
4		Mancozeb	2200	-	-	36	75	4.3
5		Sumisclex (500g/L)	500	-	-	30	68	4.0
6	Mancozeb (750 g/kg)	Tri-base blue	3000	-	-	33	70	4.1
7		Bravo	1400	-	-	19	75	4.3
8		Gp 3 F	290	-	-	18	62	4.0
9		Gp 7 F	400	-	-	28	77	4.1
10		Gp 3-11 O	500	-	-	28	70	4.1
11		Mancozeb	1000	Sumisclex	500	27	67	3.7
12		Mancozeb	1000	Bravo	1400	27	68	4.3
P =						0.79	0.43	0.47
LSD =						nsd	nsd	nsd
CV =								8.0

Comments:
 Trial designed to compare disease development and crop yield resulting from different fungicide management strategies in fababean
 No obvious sign of leaf rust or chocolate spot during trial
 Upper canopy was assessed at start of senescence for both incidence and severity of 'black spots'
 Assessed on 19 random plants about two thirds up the plant (about 8 leaflets from top of plant). Assessment on whole leaflet consisting of up to 8 leaves
 There was no apparent impact on yield from the fungicide programs in the absence of disease